
    
      This will be a first in human Phase I, ascending dose, multi-center, randomized patient study
      evaluating the efficacy, safety, PK of AK1320 MS. The study will enroll up to 4 dose
      escalating cohorts with each cohort having 2 treatment groups, the AK1320 MS group (n=7) and
      the Control group (n=3).
    
  